Abiopharma

🔍 Fitzgerald Lindsay Clinton (Executive)

Company: Gevo, Inc. (GEVO)

Report Date: 2026-03-12

Detailed Transactions and Holdings:

• Sold 20,000 shares of Common Stock at $2.5062 per share (Direct)
  Date: 2026-03-12 | Code: S | equity_swap_involved: 0 | shares_owned_after: 212,199.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-03-12 | Code: H | nature_of_ownership: By 401(k) Plan | shares_owned_after: 20,624.27 | Footnotes: F3

Footnotes:

• F1: The reported transactions were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025.
• F2: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.515 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Between August 5, 2025 and March 12, 2026, the reporting person (i) acquired 7,329.85 shares of the issuer's common stock under the issuer's 401(k) plan; and (ii) disposed of 35.32 shares of the issuer's common stock under the issuer's 401(k) plan to cover administrative fees. The information in this report is based on a plan statement dated February 27, 2026.